Cost–benefit analysis of p16INK4a immunocytology and liquid-based cytology triage after primary HPV testing for cervical cancer screening in China
Based on real-world sample data and the monetization of clinical performance metrics, this study recommends p16 as the secondary triage technology. The HPV16/18+ or (OH-HPV+ and p16+) strategy is not only the most attractive but also holds high potential for large-scale implementation in China.
Authors
- Wenxi Tang (ORCID: https://orcid.org/0000-0002-3564-3626)
- Jun Hou (ORCID: https://orcid.org/0000-0002-4387-8222)
- Dachuang Zhou
- Yuan Li (ORCID: https://orcid.org/0000-0001-5651-819X)
- Xinfeng Qu (ORCID: https://orcid.org/0000-0002-2848-6263)
- Ruifang Wu (ORCID: https://orcid.org/0000-0002-1780-6540)
- Jiayi Xi
Institutions
- China Pharmaceutical University (CN)
- Hong Kong University of Science and Technology (HK)
- Peking University Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Infectious Agents and Cancer
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1186/s13027-025-00642-6
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shenzhen Fundamental Research Program